Forest Laboratories Inc. (FRX): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Forest Laboratories ( FRX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.7%. By the end of trading, Forest Laboratories rose $0.43 (1.1%) to $41.08 on average volume. Throughout the day, 1,512,543 shares of Forest Laboratories exchanged hands as compared to its average daily volume of 1,405,600 shares. The stock ranged in a price between $40.28-$41.09 after having opened the day at $40.56 as compared to the previous trading day's close of $40.65. Other companies within the Health Care sector that increased today were: Codexis ( CDXS), up 25.4%, Delcath Systems ( DCTH), up 14.9%, Cormedix ( CRMD), up 10.0% and Cardium Therapeutics ( CXM), up 9.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. Forest Laboratories has a market cap of $10.6 billion and is part of the drugs industry. Shares are up 15.1% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Forest Laboratories a buy, 2 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Biota Pharmaceuticals ( BOTA), down 67.9%, Mast Therapeutics ( MSTX), down 30.9%, Edap TMS ( EDAP), down 14.3% and Cempra ( CEMP), down 13.9% , were all laggards within the health care sector with Regeneron Pharmaceuticals ( REGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Dow Tumbles as Trump Calls Off North Korea Summit

Dow Tumbles as Trump Calls Off North Korea Summit

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio